ESC 365 - Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings

Open Access

Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings

Session: Amyloid and acute heart failure therapy advances

Topic: Pharmacotherapy

Speaker: Doctor F. Kerwagen (Wuerzburg, DE)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Fabian Kerwagen

University Hospital Wuerzburg, Wuerzburg (Germany)

0 follower

6 more presentations in this session

Pillars of heart failure therapy: improving LV function in conventional cardiac pacing

Speaker: Assistant Professor L. Cirin (Timisoara, RO)

SGLT2 inhibitor use in underweight patients with diabetes mellitus and heart failure

Speaker: Doctor Y. Fujimoto (Tokyo, JP)

Pre- and post- discharge implementation of medical therapy in patients hospitalized due to acute heart failure: a multinational observational registry

Speaker: Doctor M. Manzoni (Brescia, IT)

Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM

Speaker: Doctor I. Araujo (Lisbon, PT)

Mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: an updated systematic review and meta-analysis of randomized clinical trials

Speaker: Doctor D. Rodolico (Pisa, IT)

Access the full session

Amyloid and acute heart failure therapy advances

Speakers: Doctor F. Kerwagen, Assistant Professor L. Cirin, Doctor Y. Fujimoto, Doctor M. Manzoni, Doctor I. Araujo...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources